Risk of fractures in patients treated with selective serotonin reuptake inhibitors (SSRI)
Selective serotonin reuptake inhibitors (SSRIs) are recommended for the treatment of anxiety and depression in children, adolescents, and adults. Treatment with SSRIs, as well as underlying clinical depression, have been suggested to lead to an increased risk of fracture, potentially mediated by a change in bone metabolism and/or risk of falls.
Question
What systematic reviews are there on the risk of fractures or changed bone mineral density in people in long-term SSRI treatment?
Identified literature
One relevant systematic review with moderate risk of bias was identified (Table 1) [1]. The systematic review reported on the risk of fracture in adults treated with either SSRIs or Selective norepinephrine reuptake inhibitors (SNRIs).
In addition, 26 relevant primary studies reporting on either risk of fracture or changes in bone mineral density in people treated with either SSRI or SNRI were also identified (Table 2) [2–27]. The primary studies have not been assessed for risk of bias.
Included studies | Population/Intervention | Outcome and Results |
Khanassov et al, (2018) [1] Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis. |
||
Qualitative analysis: 33 studies, 11 case-control, 22 cohorts Quantitative meta-analysis: 23 studies, 9 case control, 14 cohort Setting: Europe, 16 studies US, 11 studies Canada, 4 studies Asia, 2 studies Israel, 1 study |
Population: Adults on an SSRI or SNRI, with or without a formal diagnosis of depression Exposure: SSRI (29 studies) or SNRI (7 studies) Comparison: Non-users (22 studies), other antidepressants, different level of adherence or past use (9 studies) Outcome: Fracture (any type of fracture at any anatomical sites either self‐reported or identified in the hospital records) |
Risk of fracture SSRI vs control: All studies (n=23): RR 1.67 (95% CI, 1.56 to 1.79) Case-control studies (n=9): RR 1.74 (95% CI, 1.50 to 2.02) Cohort studies (n=14): RR 1.63 (95%, CI 1.49 to 1.79) Studies adjusted for depression (n=10): RR 1.62 (95% CI, 1.39 to 1.90) Studies not adjusted for depression (n=12): RR 1.73 (95% CI, 1.60 to 1.87) Association fracture & age (meta-regression): OR 1.006; p=0.173 |
Authors' conclusion: “There is sufficient albeit nonrandomized evidence that use of SSRIs substantially increases fracture risk in adults, from at least age 40 years and above, particularly when used over long periods; but counter to expectations, the degree of increased risk is largely independent of age.” |
Author Year, Reference |
Study type | Population | Relevant exposure |
Outcome: Fracture | |||
Albrecht et al 2018, [3] |
Retrospective cohort | Older adults (≥65) hospitalized with traumatic brain injury | SSRI, SNRI |
Brinton et al 2019, [4] |
Retrospective cohort | US veterans | SSRI |
Bruun et al 2018, [5] |
Case control | Hip fracture patients aged ≥65 years | SSRI |
Brännström et al 2019, [6] |
Case control | Age >65 years | SSRI, SNRI |
Carrière et al 2016, [8] |
Prospective cohort | Age >65 years | SSRI |
Cheng et al 2016, [9] |
Case control | Patients with depression | SSRI |
Coupland et al 2018, [10] |
Prospective cohort | Age 20–64 years with depression | SSRI |
Gorgas et al 2021, [11] |
Case control | Age 50–95 with hip fracture | SSRI |
Hung et al 2017, [13] |
Case control | Random sample of hip fracture patients | SSRI |
Leach et al 2017, [28] |
Case control | Australian war veterans >65 years of age | SSRI |
Munson et al 2018, [17] |
Retrospective cohort | Older adults with fragility fracture | SSRI |
Ozen et al 2019, [18] |
Retrospective cohort | Patients with rheumatoid arthritis | SSRI |
Pisa et al 2020, [19] |
Case control | Older adults without previous hip fracture | SSRI |
Souverein et al 2016, [22] |
Retrospective cohort | Antidepressant users | SSRI |
Tamblyn et al 2020, [23] |
Retrospective cohort | Older adults | SSRI, SNRI |
Torvinen-Kiiskinen et al 2017, [24] |
Retrospective cohort | Alzheimers patients | SSRI, SNRI |
Vangala et al 2020, [25] |
Case control | Maintenance hemodialysis patients | SSRI |
Wang et al 2016, [26] |
Case control | Patients with fractures | SSRI, SNRI |
Wright et al 2018, [27] |
Prospective cohort | Community-dwelling men | SSRI |
Outcome: Bone mineral density | |||
Agarwal et al 2020, [2] |
Cross sectional | Female adults ≥65 years old | SSRI, SNRI |
Calarge et al 2017, [7] |
Prospective cohort | 15–20 years with depression or anxiety | SSRI |
Ham et al 2017, [12] |
Prospective cohort | Age >45 years | SSRI |
Kang et al 2021, [14] |
Case control | Newly diagnosed osteoporosis or osteopenia | SSRI |
Larsson et al 2018, [15] |
Case control | Older women | SSRI |
Rauma et al 2016, [20] |
Retrospective cohort | Women 57–67 years of age | SSRI |
Saraykar et al 2018. [21] |
Cross sectional | Older women with high risk of fragility fractures | SSRI |
References
- Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis. Int J Geriatr Psychiatry. 2018;33(12):1688-708.
- Agarwal S, Germosen C, Kil N, Bucovsky M, Colon I, Williams J, et al. Current anti-depressant use is associated with cortical bone deficits and reduced physical function in elderly women. Bone. 2020;140.
- Albrecht JS, Rao V, Perfetto EM, Daniel Mullins C. Safety of Antidepressant Classes Used Following Traumatic Brain Injury Among Medicare Beneficiaries: A Retrospective Cohort Study. Drugs Aging. 2018;35(8):763-72.
- Brinton DL, Simpson AN, Fominaya CE, LaRue AC. Impact of selective serotonin reuptake inhibitors in the veteran population: 10-year risk outcomes. J Comp Eff Res. 2019;8(6):431-40. Available from: https://doi.org/10.2217/cer-2018-0085.
- Bruun SB, Petersen I, Kristensen NR, Cronin-Fenton D, Pedersen AB. Selective serotonin reuptake inhibitor use and mortality, postoperative complications, and quality of care in hip fracture patients: A danish nationwide cohort study. Clin Epidemiol. 2018;10:1053-71.
- Brännström J, Lövheim H, Gustafson Y, Nordström P. Association between Antidepressant Drug Use and Hip Fracture in Older People before and after Treatment Initiation. JAMA Psychiatry. 2019;76(2):172-9.
- Calarge CA, Mills JA, Janz KF, Burns TL, Schlechte JA, Coryell WH, et al. The Effect of Depression, Generalized Anxiety, and Selective Serotonin Reuptake Inhibitors on Change in Bone Metabolism in Adolescents and Emerging Adults. J Bone Miner Res. 2017;32(12):2367-74. Available from: https://doi.org/10.1002/jbmr.3238.
- Carrière I, Farré A, Norton J, Wyart M, Tzourio C, Noize P, et al. Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort. Osteoporos Int. 2016;27(11):3187-95.
- Cheng BH, Chen PC, Yang YH, Lee CP, Huang KE, Chen VC. Effects of depression and antidepressant medications on hip fracture: A population-based cohort study in Taiwan. Medicine (Baltimore). 2016;95(36):e4655. Available from: https://doi.org/10.1097/MD.0000000000004655.
- Coupland, C., Hill T, Morriss R, Moore M, Arthur A, et al. Antidepressant use and risk of adverse outcomes in people aged 20-64 years: Cohort study using a primary care database. BMC Med. 2018;16(1).
- Gorgas MQ, Torres F, Vives R, Lopez-Rico I, Capella D, Pontes C. Effects of selective serotonin reuptake inhibitors and other antidepressant drugs on the risk of hip fracture: a case-control study in an elderly Mediterranean population. Eur J Hosp Pharm. 2021;28(1):28-32. Available from: https://doi.org/10.1136/ejhpharm-2019-001893.
- Ham AC, Aarts N, Noordam R, Rivadeneira F, Ziere G, Zillikens MC, et al. Use of Selective Serotonin Reuptake Inhibitors and Bone Mineral Density Change: A Population-Based Longitudinal Study in Middle-Aged and Elderly Individuals. J Clin Psychopharmacol. 2017;37(5):524-30.
- Hung SC, Lin CH, Hung HC, Lin CL, Lai SW. Use of Selective Serotonin Reuptake Inhibitors and Risk of Hip Fracture in the Elderly: A Case-Control Study in Taiwan. J Am Med Dir Assoc. 2017;18(4):350-4.
- Kang S, Han M, Park CI, Jung I, Kim EH, Boo YJ, et al. Use of serotonin reuptake inhibitors and risk of subsequent bone loss in a nationwide population-based cohort study. Sci Rep. 2021;11(1):13461.
- Larsson B, Mellstrom D, Johansson L, Nilsson AG, Lorentzon M, Sundh D. Normal Bone Microstructure and Density But Worse Physical Function in Older Women Treated with Selective Serotonin Reuptake Inhibitors, a Cross-Sectional Population-Based Study. Calcif Tissue Int. 2018;103(3):278-88. Available from: https://doi.org/10.1007/s00223-018-0427-z.
- Leach MJ, Pratt NL, Roughead EE. Risk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case–Control Study in Australia. Drugs Real World Outcomes. 2017;4(2):87-96.
- Munson JC, Bynum JPW, Bell JE, McDonough C, Wang Q, Tosteson T, et al. Impact of prescription drugs on second fragility fractures among US Medicare patients. Osteoporos Int. 2018;29(12):2771-9.
- Ozen G, Pedro S, Wolfe F, Michaud K. Medications associated with fracture risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(8):1041-7.
- Pisa FE, Reinold J, Kollhorst B, Haug U, Schink T. Individual Antidepressants and the Risk of Fractures in Older Adults: A New User Active Comparator Study. Clin Epidemiol. 2020;12:667-78. Available from: https://doi.org/10.2147/CLEP.S222888.
- Rauma PH, Honkanen RJ, Williams LJ, Tuppurainen MT, Kroger HP, Koivumaa-Honkanen H. Effects of antidepressants on postmenopausal bone loss - A 5-year longitudinal study from the OSTPRE cohort. Bone. 2016;89:25-31. Available from: https://doi.org/10.1016/j.bone.2016.05.003.
- Saraykar S, John V, Cao B, Hnatow M, Ambrose CG, Rianon N. Association of Selective Serotonin Reuptake Inhibitors and Bone Mineral Density in Elderly Women. J Clin Densitom. 2018;21(2):193-9. Available from: https://doi.org/10.1016/j.jocd.2017.05.016.
- Souverein PC, Abbing-Karahagopian V, Martin E, Huerta C, de Abajo F, Leufkens HGM, et al. Understanding inconsistency in the results from observational pharmacoepidemiological studies: The case of antidepressant use and risk of hip/femur fractures. Pharmacoepidemiol Drug Saf. 2016;25:88-102.
- Tamblyn R, Bates DW, Buckeridge DL, Dixon WG, Girard N, Haas JS, et al. Multinational Investigation of Fracture Risk with Antidepressant Use by Class, Drug, and Indication. J Am Geriatr Soc. 2020;68(7):1494-503.
- Torvinen-Kiiskinen S, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, et al. Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer's disease. Int J Geriatr Psychiatry. 2017;32(12):e107-e15.
- Vangala C, Niu J, Montez-Rath ME, Yan J, Navaneethan SD, Winkelmayer WC. Selective Serotonin Reuptake Inhibitor Use and Hip Fracture Risk Among Patients on Hemodialysis. Am J Kidney Dis. 2020;75(3):351-60.
- Wang CY, Fu SH, Wang CL, Chen PJ, Wu FLL, Hsiao FY. Serotonergic antidepressant use and the risk of fracture: a population-based nested case–control study. Osteoporos Int. 2016;27(1):57-63.
- Wright NC, Hooker ER, Nielson CM, Ensrud KE, Harrison SL, Orwoll ES, et al. The epidemiology of wrist fractures in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int. 2018;29(4):859-70. Available from: https://doi.org/10.1007/s00198-017-4349-9.
- Leach MJ, Pratt NL, Roughead E. The risk of hip fracture in older people after switching between or concurrently using mirtazapine and other antidepressants. Pharmacoepidemiol Drug Saf. 2017;26:164.
Literature search
Embase via Elsevier 2 September 2021
The final search result, usually found at the end of the documentation, forms the list of abstracts. /de = Term from the EMTREE controlled vocabulary; /exp = Includes terms found below this term in the EMTREE hierarchy /mj = Major Topic; :ab = Abstract; :au = Author; :ti = Article Title; :ti,ab = Title or abstract; * = Truncation; ' ' = Citation Marks; searces for an exact phrase; NEAR/n = Requests terms that are within 'n' words of each other in either direction; NEXT/n = Requests terms that are within 'n' words of each other in the order specified |
||
Search terms | Items found | |
Population: | ||
1. | 'bone density'/exp OR 'bone demineralization'/exp OR 'osteolysis'/exp OR 'fracture'/de OR 'fragility fracture'/de | 330 743 |
2. | (bone NEAR/4 (loss OR fragil* OR mass OR density OR demineralization)):ti,ab,kw | 137 310 |
3. | osteoporo*:ti,ab,kw OR osteolysi*:ti,ab,kw OR fracture*:ti,ab,kw OR decalcificat*:ti,ab,kw | 424 199 |
4. | 1 OR 2 OR 3 | |
Intervention: SSRI/SNRI | ||
5. | 'serotonin uptake inhibitor'/exp | 294 122 |
6. | 'antidepressant agent'/de | 103 924 |
7. | (((serotonin OR noradrenaline OR norepinephrine OR '5 ht' OR '5 hydroxytryptamine') NEAR/3 (uptake OR reuptake) NEAR/3 inhibitor*):ti,ab,kw) OR 'anti depress*':ti,ab,kw OR ssri:ti,ab,kw OR snri:ti,ab,kw | 36 573 |
8. | fluvoxamin*:ti,ab,kw OR fluoxetin*:ti,ab,kw OR paroxetin*:ti,ab,kw OR sertralin*:ti,ab,kw OR citalopram:ti,ab,kw OR escitalopram:ti,ab,kw OR vilazodon*:ti,ab,kw OR trazodon*:ti,ab,kw | 40 577 |
9. | desvenlafaxin*:ti,ab,kw OR duloxetin*:ti,ab,kw OR venlafaxin*:ti,ab,kw OR levomilnacipran:ti,ab,kw OR milnacipran:ti,ab,kw OR renboxetin:ti,ab,kw OR edronax:ti,ab,kw | 11 683 |
10. | 5 OR 6 OR 7 OR 8 OR 9 | |
Study types: systematic reviews | ||
11. | 'systematic review'/exp OR 'meta analysis'/exp OR 'systematic review':ti,ab,kw OR 'meta analysis':ti,ab,kw OR metaanalysis:ti,ab,kw | |
Combined sets | ||
12. | 4 AND 10 | 5 161 |
13. | 11 AND 12 | 266 |
Final result | ||
14. | 266 |
Medline via OvidSP 2 September 2021
The final search result, usually found at the end of the documentation, forms the list of abstracts. .ab. = Abstract; .ab,ti. = Abstract or title; .af. = All fields; Exp = Term from the Medline controlled vocabulary, including terms found below this term in the MeSH hierarchy; .sh. = Term from the Medline controlled vocabulary; .ti. = Title; / = Term from the Medline controlled vocabulary, but does not include terms found below this term in the MeSH hierarchy; * = Focus (if found in front of a MeSH-term); * or $ = Truncation (if found at the end of a free text term); .mp = Text, heading word, subject area node, title; “ “ = Citation Marks; searches for an exact phrase; ADJn = Positional operator that lets you retrieve records that contain your terms (in any order) within a specified number (n) of words of each other. |
||
Search terms | Items found | |
Population: Osteoporosis | ||
1. | exp Osteoporosis/ or exp Bone Demineralization, Pathologic/ or Bone density/ or Osteoporotic Fractures/ or Osteolysis/ [osteoporosis MeSH] | 103 161 |
2. | (osteoporo* or osteolysi* or fracture* or decalcificat* or (bone adj3 (loss or fragil* or mass or density or demineralization))).tw,kw | 384 664 |
3. | 1 or 2 | 403 658 |
Intervention: SSRI/SNRI | ||
4. | exp Serotonin Uptake Inhibitors/ or exp Antidepressive Agents/ or exp "Serotonin and Noradrenaline Reuptake Inhibitors"/ [SSRI & SNRI] | 165143 |
5. | (((serotonin or 5-HT or 5-Hydroxytryptamine or noradrenaline or norepinephrine) adj2 (uptake or reuptake) adj2 inhibitor*) or (anti-depress* or anti depress*)).tw,kw. [SSRI SNRI] | 22155 |
6. | Fluvoxamine/ or Fluoxetine/ or Paroxetine/ or Sertraline/ or Citalopram/ or Vilazodone Hydrochloride/ or Trazodone/ [SSRI] | 22444 |
7. | Desvenlafaxine Succinate/ or Duloxetine Hydrochloride/ or Venlafaxine Hydrochloride/ or exp Milnacipran/ [SNRI] | 4791 |
8. | (Fluvoxamin* or fluoxetin* or paroxetin* or Sertralin* or citalopram or escitalopram or vilazodon* or trazodon*).tw,kw. [SSRI] | 28773 |
9. | (desvenlafaxin* or duloxetin* or venlafaxin*or levomilnacipran or milnacipran or Renboxetin or edronax).tw,kw [SNRI] | 3484 |
10. | or/4-9 | 177747 |
Study types: systematic reviews | ||
11. | (Systematic Review or Meta-Analysis).pt. or Cochrane Database Syst Rev.ja. or ((systematic adj3 review) or "meta analys*" or metaanalys*).ti,ab | 351528 |
Combined sets | ||
12. | 3 and 10 | 742 |
13. | 11 and 12 | 41 |
Final result | ||
14. | 13 | 41 |
Scopus via Elsevier 2 September 2021
The final search result, usually found at the end of the documentation, forms the list of abstracts. TITLE-ABS-KEY = Title or abstract or keywords; ALL = All fields; PRE/n = "precedes by". The first term in the search must precede the second by a specified number of terms (n).; W/n = "Within". The terms in the search must be within a specified number of terms (n) in any order.; * = Truncation; “ “ = Citation Marks; searches for an exact phrase; LIMIT-TO (SRCTYPE, "j" = Limit to source type journal; LIMIT-TO (DOCTYPE, "ar" = Limit to document type article; LIMIT-TO (DOCTYPE, "re" = Limit to document type review |
||
Search terms | Items found | |
Population: Bone loss | ||
1. | TITLE-ABS-KEY ( osteoporo* OR osteolysi* OR decalcificat* OR fracture* ) | 996 564 |
2. | TITLE-ABS-KEY ( bone W/3 ( loss OR fragil* OR mass OR density OR demineralization ) ) | 164 592 |
3. | 1 OR 2 | 1 062 787 |
Intervention: SSRI/SNRI | ||
4. | TITLE-ABS-KEY ( ( ( serotonin OR noradrenaline OR norepinephrine OR 5-ht OR 5-hydroxytryptamine ) W/2 ( uptake OR reuptake ) W/2 inhibitor* ) OR anti-depress* OR ssri OR snri ) | 66 801 |
5. | TITLE-ABS-KEY ( fluvoxamin* OR fluoxetin* OR paroxetin* OR sertralin* OR citalopram OR escitalopram OR vilazodon* OR trazodon* OR venlafaxin* OR desvenlafaxin* OR duloxetin* OR levomilnacipran OR milnacipran OR renboxetin OR edronax ) | 104 734 |
6. | 4 OR 5 | 134 334 |
Study types: Systematic reviews | ||
7. | ( TITLE-ABS-KEY ( ( systematic W/2 review ) OR "meta analys*" OR metaanalys* ) OR ( SRCTITLE ( cochrane ) ANDDOCTYPE ( re ) ) ) | |
Combined sets | ||
8. | 3 AND 6 | 2 595 |
9. | 7 AND 8 | 216 |
Final result | ||
10. | 216 |